Ask the Experts Webinar: Disease Modifying Therapies Clinical Guidance

Activity Title: Ask the Experts Webinar: Disease Modifying Therapies Clinical Guidance
Activity Format: Live Webinar
Start Date: 10/22/2026
End Date: 01/22/2027
Platform: Zoom
Estimated Time: 1 hour

Activity Description
This webinar will bring together experts to review the evolving therapeutic pipeline of disease modifying therapies for epilepsy and outline key considerations for safe, ethical, and equitable implementation. The session will address clinical readiness, infrastructure and workforce needs, equitable access to advanced therapies, consent and long-term follow-up, and strategies to support both academic and community practices.

Target Audience
This activity is designed for epileptologists, neurologists, nurses, advanced practice providers, pharmacists, and other healthcare professionals who care for patients with epilepsy.

Learning Objectives
Upon completion of this activity, participants will be able to:

Assess the current and future landscape of disease modifying therapies for epilepsy.
Recognize necessary infrastructure to implement and provide follow-up for these therapies.
Examine ways to promote equitable access to advanced therapies for appropriate patients.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The American Epilepsy Society is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Conflict of Interest & Disclosure
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the American Epilepsy Society requires that all individuals in a position to control the content of this educational activity disclose all financial relationships with any ineligible company (defined as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) within the past 24 months. All relevant financial relationships have been identified and mitigated prior to the start of this activity.

Name of Individual	Individual's Role(s) in Activity	Name of Ineligible Company(s)	Nature of Relationship(s)	Mechanism(s) Implemented to Mitigate Relevant Financial Relationships Appropriate to Role(s) in the Activity
Gupta, Kunal	Presenter & Planner	N/A	None	N/A
Joshi, Sucheta	Presenter & Planner	N/A	None	N/A
McNeilly, Michelle	AES Staff	N/A	None	N/A
Shahram, Izadyal	Disclosure Mitigator	N/A	None	N/A
Ziobro, Julie	Presenter & Planner	N/A	None	N/A

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.

Kunal Gupta, MD, PhD, FAANS
Dr Kunal Gupta, MD, PhD, FAANS, Associate Professor of Neurological Surgery, is an epilepsy and functional neurosurgeon at the Medical College of Wisconsin. Dr Gupta specializes in the open and minimally invasive surgical treatment of epilepsy and deep brain stimulation (DBS) and focused ultrasound (FUS) for movement disorders. Dr Gupta also runs a basic science laboratory group, investigating new methods to treat epilepsy through signaling pathway modulation and gene therapy. His lab uses animal models to understand the pathways responsible for epileptogenesis, the process by which the brain is rewired to support epileptic circuits, and develop novel therapeutic targets for seizure prevention.

Sucheta Joshi, MD, MS, FCNS, FAES
Sucheta Joshi, MD, MS, FCNS, FAES, is a Pediatric Neurologist and Epileptologist at Children's Hospital Los Angeles. She completed training at University of California San Francisco, Stanford University and University of Michigan School of Public Health. Dr. Joshi is Professor in Pediatric Neurology, USC KSOM, and the Medical Director of the Comprehensive Epilepsy Center at CHLA. Her clinical interests involve difficult-to-treat pediatric epilepsy, EEG and EEG monitoring. Her clinical and scholarly interests also include improving access to epilepsy care for children in medically underserved areas using innovative methods for epilepsy care such as telemedicine and telementoring, and transition of adolescents with epilepsy to adult care.

Julie Ziobro, MD, PhD
Julie Ziobro, MD, PhD is an Assistant Professor of Pediatrics in the Division of Pediatric Neurology at the University of Michigan. She is a K08 scholar, studying basic mechanisms in genetic epilepsies with a focus on PCDH19 and Dravet sydrome. Her clinical interests include precision therapies for genetic epilepsies and implementation of advanced targeted therapies for epilepsy.

For questions regarding this activity, please contact the American Epilepsy Society Education Department at education@aesnet.org or call (312) 883 3800.